Anti-EGFL8/ C6orf8/ NG3 functional antibody
Anti-EGFL8/ C6orf8/ NG3 functional antibody for cell culture, ELISA & in-vivo assay
Go to EGFL8/EGFL8 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0901-Ab-1/ GM-Tg-hg-SE0901-Ab-2 | Anti-Human EGFL8 monoclonal antibody | Human |
GM-Tg-rg-SE0901-Ab-1/ GM-Tg-rg-SE0901-Ab-2 | Anti-Rat EGFL8 monoclonal antibody | Rat |
GM-Tg-mg-SE0901-Ab-1/ GM-Tg-mg-SE0901-Ab-2 | Anti-Mouse EGFL8 monoclonal antibody | Mouse |
GM-Tg-cynog-SE0901-Ab-1/ GM-Tg-cynog-SE0901-Ab-2 | Anti-Cynomolgus/ Rhesus macaque EGFL8 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0901-Ab-1/ GM-Tg-felg-SE0901-Ab-2 | Anti-Feline EGFL8 monoclonal antibody | Feline |
GM-Tg-cang-SE0901-Ab-1/ GM-Tg-cang-SE0901-Ab-2 | Anti-Canine EGFL8 monoclonal antibody | Canine |
GM-Tg-bovg-SE0901-Ab-1/ GM-Tg-bovg-SE0901-Ab-2 | Anti-Bovine EGFL8 monoclonal antibody | Bovine |
GM-Tg-equg-SE0901-Ab-1/ GM-Tg-equg-SE0901-Ab-2 | Anti-Equine EGFL8 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0901-Ab-1/ GM-Tg-hg-SE0901-Ab-2; GM-Tg-rg-SE0901-Ab-1/ GM-Tg-rg-SE0901-Ab-2; GM-Tg-mg-SE0901-Ab-1/ GM-Tg-mg-SE0901-Ab-2; GM-Tg-cynog-SE0901-Ab-1/ GM-Tg-cynog-SE0901-Ab-2; GM-Tg-felg-SE0901-Ab-1/ GM-Tg-felg-SE0901-Ab-2; GM-Tg-cang-SE0901-Ab-1/ GM-Tg-cang-SE0901-Ab-2; GM-Tg-bovg-SE0901-Ab-1/ GM-Tg-bovg-SE0901-Ab-2; GM-Tg-equg-SE0901-Ab-1/ GM-Tg-equg-SE0901-Ab-2 |
Products Name | Anti-EGFL8 monoclonal antibody |
Format | mab |
Target Name | EGFL8 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-EGFL8 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0901-Ag-1 | Recombinant multi-species EGFL8/ C6orf8/ NG3 protein |
Cytokine | GM-Tg-g-SE0901-Ag-1 | EGF-like-domain, multiple 8 (EGFL8) protein |
ORF Viral Vector | pGMLP004973 | human EGFL8 Lentivirus plasmid |
ORF Viral Vector | vGMLP004973 | human EGFL8 Lentivirus particle |
ORF Viral Vector | pGMLPm004581 | mouse Egfl8 Lentivirus plasmid |
ORF Viral Vector | vGMLPm004581 | mouse Egfl8 Lentivirus particle |
Target information
Target ID | GM-SE0901 |
Target Name | EGFL8 |
Gene ID | 80864,81701,406166,717145,481725,101095824,782820 |
Gene Symbol and Synonyms | AGPAT1,C6orf8,EGFL8,NG3 |
Uniprot Accession | Q99944,Q6MG84 |
Uniprot Entry Name | EGFL8_HUMAN,EGFL8_RAT |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Cytokine Target |
Disease | N/A |
Gene Ensembl | ENSG00000241404 |
Target Classification | N/A |
The target: EGFL8, gene name: EGFL8, also named as C6orf8, NG3. Predicted to enable signaling receptor binding activity. Predicted to be involved in anatomical structure development. Predicted to act upstream of or within in utero embryonic development. Predicted to be active in cell surface and extracellular region. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.